Moleculin Biotech (MBRX) News Today → The most important AI company you've never heard of (From Manward Press) (Ad) Free MBRX Stock Alerts $4.92 +0.07 (+1.44%) (As of 05/15/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15 at 8:38 AM | prnewswire.comMoleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)May 15 at 3:38 AM | americanbankingnews.comMoleculin Biotech (NASDAQ:MBRX) Earns Sell Rating from Analysts at StockNews.comMay 14 at 9:44 AM | msn.comMoleculin Biotech, Inc. (NASDAQ:MBRX) Q1 2024 Earnings Call TranscriptMay 14 at 4:43 AM | finance.yahoo.comMoleculin Biotech Inc (MBRX) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances ...May 13 at 6:43 PM | finanznachrichten.deMoleculin Biotech, Inc.: Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 13 at 7:30 AM | prnewswire.comMoleculin Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 10, 2024 | investorplace.comMBRX Stock Earnings: Moleculin Biotech Beats EPS for Q1 2024May 10, 2024 | markets.businessinsider.comMoleculin Biotech’s Annamycin Shows Promising Efficacy in AML Treatment, Backed by Strong Clinical Results and Buy RatingMay 9, 2024 | prnewswire.comMoleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for AnnamycinMay 8, 2024 | prnewswire.comMoleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and WebcastMay 7, 2024 | prnewswire.comMoleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject DataMay 7, 2024 | americanbankingnews.comStockNews.com Begins Coverage on Moleculin Biotech (NASDAQ:MBRX)May 2, 2024 | prnewswire.comMoleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024May 1, 2024 | prnewswire.comMoleculin Announces Formation of Scientific Advisory Board to Support Development of AnnamycinApril 26, 2024 | finanznachrichten.deJTC Team, LLC: Moleculin Biotech Participates in Virtual Investor "What This Means" Segment Hosted by JTC TeamApril 18, 2024 | markets.businessinsider.comMoleculin Biotech Says EMA Grants Orphan Drug Designation To Annamycin To Treat AMLApril 18, 2024 | prnewswire.comEuropean Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)April 12, 2024 | investing.comMoleculin Biotech Inc (MBRX)April 10, 2024 | markets.businessinsider.comMoleculin Biotech Reveals Positive Anti-cancer Data For Annamycin With Non-cardiotoxic EffectsApril 10, 2024 | prnewswire.comMoleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic PropertiesMarch 28, 2024 | finance.yahoo.comMoleculin to Present at the MedInvest Biotech & Pharma Investor ConferenceMarch 27, 2024 | finance.yahoo.comMoleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AMLMarch 27, 2024 | prnewswire.comMoleculin to Participate in the Virtual Investor Lunch Break: The Moleculin OpportunityMarch 26, 2024 | finance.yahoo.comMoleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2023 Earnings Call TranscriptMarch 25, 2024 | finanznachrichten.deMoleculin Biotech, Inc.: Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML TrialMarch 25, 2024 | marketbeat.comTrading was temporarily halted for "MBRX" at 10:03 AM with a stated reason of "LULD pause." Trading set to resume at 10:03 AM. March 25, 2024 | markets.businessinsider.comMoleculin Biotech Reports Positive Interim Data From MB-106 Phase 1B/2 Study In AMLMarch 25, 2024 | finance.yahoo.comMoleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML TrialMarch 23, 2024 | finanznachrichten.deMoleculin Biotech, Inc.: Moleculin Reports Full Year 2023 Financial ResultsMarch 22, 2024 | investorplace.comMBRX Stock Earnings: Moleculin Biotech Reported Results for Q4 2023March 22, 2024 | finance.yahoo.comMoleculin Biotech Inc Reports Fiscal Year 2023 Financial ResultsMarch 22, 2024 | prnewswire.comMoleculin Reports Full Year 2023 Financial ResultsMarch 22, 2024 | marketbeat.comTrading was temporarily halted for "MBRX" at 07:03 PM with a stated reason of "News pending."March 21, 2024 | investing.comMoleculin Biotech announces 1-for-15 reverse stock splitMarch 21, 2024 | benzinga.comA Preview Of Moleculin Biotech's EarningsMarch 20, 2024 | finanznachrichten.deMoleculin Biotech, Inc.: Moleculin Announces Reverse Stock SplitMarch 20, 2024 | prnewswire.comMoleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and WebcastMarch 19, 2024 | finance.yahoo.comMoleculin Announces Reverse Stock SplitMarch 12, 2024 | finance.yahoo.comMoleculin to Present at the 36th Annual ROTH ConferenceFebruary 6, 2024 | finance.yahoo.comHere's Why We're A Bit Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn SituationJanuary 24, 2024 | finance.yahoo.comMoleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3December 21, 2023 | finance.yahoo.comMoleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-MarketDecember 15, 2023 | nasdaq.comHC Wainwright & Co. Initiates Coverage of Moleculin Biotech (MBRX) with Buy RecommendationDecember 14, 2023 | markets.businessinsider.comBuy Rating for Moleculin Biotech Amid Promising Annamycin Trial Results in AMLDecember 11, 2023 | markets.businessinsider.comMoleculin Presents Preliminary Efficacy Data Of Annamycin In Acute Myeloid LeukemiaDecember 11, 2023 | finance.yahoo.comMoleculin Presents Positive Interim Data from Phase 1B/2 Clinical Trial in AML at Meeting with KOL's in Conjunction with ASH Annual MeetingDecember 1, 2023 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Moleculin Biotech (MBRX)November 14, 2023 | finance.yahoo.comMoleculin Biotech, Inc. (NASDAQ:MBRX) Q3 2023 Earnings Call TranscriptNovember 13, 2023 | msn.comMoleculin Biotech gains after early data for lead cancer therapyNovember 13, 2023 | finanznachrichten.deMoleculin Biotech, Inc.: Moleculin Reports Third Quarter 2023 Financial Results Get Moleculin Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Urgent Nvidia Warning (Ad)Could Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space. Click here to access… MBRX Media Mentions By Week MBRX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MBRX News Sentiment▼0.870.55▲Average Medical News Sentiment MBRX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MBRX Articles This Week▼121▲MBRX Articles Average Week Get Moleculin Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: MIRA News Today AKTX News Today ABVC News Today ELAB News Today ERNA News Today MTEM News Today IMNN News Today GHSI News Today PPBT News Today CMMB News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MBRX) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersUrgent Nvidia WarningAltimetryCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaGold Set to EXPLODE!Gold Safe ExchangeProtect Your Bank Account Before It’s Too LateWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moleculin Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.